Johnson & Johnson's Xarelto has more results to back up its artery disease case—and help it extend its indication lead over the competition.

Lupin has been trying for two years to bring its plant in Goa, India, up to FDA standards, but a new warning letter says more improvements are needed.

Amazon, seen as a pharma threat, may go after medical device and supply sales before it leaps into drugs, a new report suggests.

Launched for lung cancer awareness month in November, the “tALK+” (Talk Positive) campaign focuses on the ALK-positive form of lung cancer.

If recent numbers—and a new doctor survey—are any indication, Tesaro's Zejula has the lead in ovarian cancer. But that could change.

Now that Prostvac has failed as a stand-alone therapy, Bavarian Nordic's MVA-BN RSV vaccine is now extra-important.

Merck and GSK are coping with hepatitis A vaccine shortages as the U.S. is experiencing deadly outbreaks.

Pharma can usually look back at FDA enforcement letters for insight into the agency's thinking on marketing communications. Not this year.